Molecular Pathology of Adrenocortical Cancer
|
Molecular Pathology of Adrenocortical Cancer |
About Contact |
| Home | • | Compounds | • | Expert Opinion | • | Trial Analysis | • | Pathways | • | Diseases | • | Workspace | • | TOUR |
 |
|
| Welcome to CuraBase® - The Curated and Collaborative Cancer Database Click Here to Learn More about CuraBase® |
|
Access to CuraBase® is free-of-charge for users in Academia or Non-Profit Organizations. |
|
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| beta-catenin | WNT Signaling |
adrenocortical carcinoma | 30% | |||||||||
| beta-catenin | WNT Signaling |
adrenocortical carcinomas | 85% | Abnormal cytoplasmic or nuclear accumulation of β-catenin | ||||||||
| EGFR (ErbB-1 receptor) | Receptor Tyrosine Kinase Signaling |
adrenocortical carcinoma | 90% | overexpression | ||||||||
| IGF-2 | Insulin receptor signaling pathway |
adrenocortical carcinoma | 90% | overexpression | ||||||||
| p53 | p53 Tumor Suppressor Pathway |
adrenocortical carcinoma | 30% |
| CANCER.GOV PDQ® - Standard Treatments for Adrenocortical Cancer | ||
